Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Paget's Disease of Bone
Conditions
Paget's Disease of Bone
Trial Timeline
Jan 1, 2001 → Apr 1, 2011
NCT ID
NCT00051636About Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid is a phase 3 stage product being developed by Novartis for Paget's Disease of Bone. The current trial status is completed. This product is registered under clinical trial identifier NCT00051636. Target conditions include Paget's Disease of Bone.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00051636 | Phase 3 | Completed |
Competing Products
5 competing products in Paget's Disease of Bone
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 77 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 85 |
| Zoledronic Acid | Novartis | Approved | 85 |
| Zoledronic acid | Novartis | Approved | 85 |
| alendronate | Organon | Phase 3 | 72 |